IP Library Granted Patent US 10,442,852
Granted Patent B2
US 10,442,852 · App. 15/847,719 · Granted Oct 15, 2019

Methods and compositions for treatment of symptoms associated with intracranial hemorrhage

Inventors: Marian L. Kruzel (Houston, TX); Jaroslaw Aronowski (Houston, TX)
Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
C07K14/79A61P9/00C07K16/00A61K38/00C07K2317/21C07K2317/41C07K2317/53C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,442,852
App. No.
15/847,719
Granted
Oct 15, 2019
Kind
B2
Abstract

Methods and compositions are provided for the treatment of a patient with intracranial hemorrhage (ICH). Methods include the use of the products of recombinant constructs such as those that contain lactoferrin, as well as fusion protein constructs of lactoferrin and Fc domain for IgG.

Claims (19)

1. A recombinant polypeptide comprising:

a lactoferrin sequence;

an immunoglobulin IgG2 Fc domain sequence fused to said lactoferrin sequence; and

an IgG2 hinge sequence, wherein said hinge is located between said lactoferrin sequence and said Fc domain sequence,

wherein the amino acid sequence of said recombinant polypeptide has a sequence of SEQ ID NO: 2.

2. The polypeptide of claim 1 , wherein the polypeptide is glycosylated to form a glycosylated polypeptide.

3. The polypeptide of claim 2 , wherein the glycosylated polypeptide is N-linked.

4. A composition comprising the polypeptide of claim 1 in a pharmaceutically acceptable carrier, wherein said carrier is aqueous, powder, or saline, and wherein said composition is frozen or lyophilized.

5. A method of treating or preventing intracranial hemorrhage or a related disorder in a subject, comprising administering to said subject an effective amount of a composition comprising the polypeptide of claim 1 , and wherein said polypeptide is administered intrathecally, buccally, orally, topically, intradermally, subcutaneously, intranasally, intramuscularly, intravenously, intra-arterially, or directly into a tissue site.

6. The method of claim 5 , wherein said related disorder is a cognitive or neurological deficit, inflammation, infection, edema or brain atrophy due to intracranial hemorrhage.

7. An isolated recombinant polynucleotide molecule comprising a coding sequence for a polypeptide comprising:

a lactoferrin coding sequence;

an immunoglobulin IgG2 Fc domain coding sequence fused to said lactoferrin coding sequence; and

an IgG2 hinge coding sequence, wherein said hinge is located between said lactoferrin coding sequence and said Fc domain coding sequence; and

wherein polypeptide has a sequence of SEQ ID NO: 2.

8. The polynucleotide of claim 7 , wherein the nucleic acid sequence of said polynucleotide comprises SEQ ID NO: 1.

9. An expression vector comprising a heterologous promoter sequence linked to a polynucleotide of claim 7 .

10. The expression vector of claim 9 , wherein said vector is expressed in a mammalian cell, a CHO cell, a yeast cell, or an insect cell.

11. A host cell, comprising a polynucleotide molecule of claim 7 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2018
From: ARONOWSKI, JAROSLAW; KRUZEL, MARIAN L
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 045793/0090 →
Continuity (3)
Continuation In Part PCTUS2016039362 · Jun 24, 2016
Provisional Application 62184049 · Jun 24, 2015
Related Publication 20180127486A1 · May 10, 2018
Cited By (9)
US 12,190,589 US 12,223,537 US 12,236,652 US 12,254,650 US 12,272,091 US 12,299,714 US 12,380,492 US 12,406,503 US 12,432,321